Αρχική World News Opinion: ‘We’re making headway, but we can’t be complacent’

Opinion: ‘We’re making headway, but we can’t be complacent’

Michelle Mitchell chief executive Cancer Research UKEquality, Diversity and Inclusion strategy – which we published a few weeks ago – we knew accountability had to be one of our key principles. A strategy is only impactful if it’s implemented, and measuring progress is how we will hold ourselves to account.

So I’m pleased that we’re publishing our gender and ethnicity pay gap reports today. This is the first time we’ve published our ethnicity pay gap reporting – which takes us further than legal requirements, but I feel is an important way to keep ourselves accountable.

Both reports we publish today show that we’re making some headway, and this is the result of concerted effort over the past few years to improve the diversity of our workforce. But these only tell part of the story, and we still have work to do.

I’m pleased to say we’ve made progress in closing our gender pay gap. Our mean gender pay gap is now 15.0%, down from 15.8% last year and 18.7% in 2017, when we first reported it. We have taken further steps towards gender parity in technology, with women making up 41% of the team – putting us far ahead of the national average at 19%. And we increased the proportion of women at director level and above to 57%, past our 50% target the year before.

We have a pay gap in favour of ethnic minority employees, meaning people from ethnic minority backgrounds are paid on average 9.5% more than white employees.

But we aren’t at all complacent, for two reasons.

The first reason is that on their own, these statistics don’t tell the full story. We have relatively low numbers of people from ethnic minority backgrounds in our team, for example, and from talking to our people, we know that colleagues from ethnic minority backgrounds are less likely to feel like they belong at Cancer Research UK. I am committed to changing this. We want everyone to feel included, and supported to thrive. We have also been through a huge amount of change this year because of the pandemic, and these figures are a snapshot from April 2020, which do not take those changes into account.

The second reason we aren’t complacent is we still have a long way to go. Our gender pay gap is reducing, but it’s still there, and our median pay gap has increased. This is because we’ve opened new shops and superstores. Our retail roles are some of the lower paid roles, and are predominantly female – which is in line with the rest of the retail sector.

So, our work continues. We want to be a more inclusive organisation, and a charity where everyone feels like they belong, and are supported to do their best work. And these pay gap reports can be a useful metric of our progress.

As you’d expect, we have targets in place to increase ethnic diversity and the proportion of women in leadership positions. But we’re also working on our recruitment and selection processes, improving our flexible working offer and consulting with external experts who will challenge us and help us improve. We’re also focusing on some new initiatives this year, such as a race fluency programme, and reverse mentoring – where senior leaders are matched with junior employees from underrepresented groups.

I hope these initiatives will, in time, positively impact our pay gaps as well as our people’s broader experience of work at Cancer Research UK. In time, I am sure that these steps will move us further along in our mission too – it’s well proven that more diverse organisations perform better, and to reach our ambitious goals of beating cancer, we’ll have to optimise every single aspect of our work.

In sharing these reports, we intend to promote transparency in how we’re doing today and set ourselves up to take greater steps forward tomorrow. We’re moving forward, and so I’m optimistic about our future – but we’ve got to keep this momentum going.

Michelle Mitchell is the chief executive of Cancer Research UK

More on this topic

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

FDA Approves Pembrolizumab Combination for the First-Line Treatment of Cervical Cancer

On 13 October 2021, the US Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) in combination with chemotherapy, with or without bevacizumab, for...

From Scan to Scan: The Challenges of Living with Metastatic Cancer

October 15, 2021, by NCI Staff Bethany Ross has been living with metastatic neuroendocrine cancer since she was diagnosed in 2018. Credit: Used with permission from...

The award-winning researcher behind next generation sequencing

Next generation sequencing (NGS) has given the genomic research community ultra-high throughput, scalability, and speed that could only be dreamed of 20 years ago....

Many Breast Cancer Patients Use Cannabis to Manage Symptoms But Don’t Tell Their Doctors

Cancer and cancer treatment come with many side effects, including nausea, vomiting, and pain. In addition to the physical toll, the impacts to a...

Medicare Open Enrollment Starts Tomorrow!

Medicare open enrollment is upon us for 2022. If you are a Medicare recipient, this is the time of year when you can make...

Cancer in My Community: Providing Supportive Care in Serbia

Cancer in My Community is a Cancer.Net Blog series that shows the global impact of cancer and how people work to care for those with...